Table 2.
Comparison between score and virological and immunological factors.
| Statistics | p-Value | |
|---|---|---|
| Time to HIV diagnosis (y) | −0.155 | 0.309 |
| CD4+ T-cell count at diagnosis (cell/mmc) | −0.402 | 0.012 |
| CD4+ T-cell count at diagnosis (%) | −0.380 | 0.020 |
| CD4+ T-cell count last determination (cell/mmc) | −0.386 | 0.009 |
| CD4+ T-cell count last determination (%) | −0.480 | 0.001 |
| Clinical progression to AIDS | <0.001 | |
| no | 8.8 (1.1) | |
| yes | 12.9 (2) | |
| Development of resistance to ART | 0.451 | |
| no | 9.8 (2.1) | |
| yes | 10.4 (2.7) | |
| HIV-RNA levels at diagnosis (cp/mL) | −0.116 | 0.502 |
| HIV-RNA levels last determination (cp/mL) | 0.010 | 0.949 |
| HIV-RNA levels last determination (cp/mL) | 0.949 | |
| <20 cp/mL | 9.9 (2.3) | |
| >20 cp/mL | 10 (2.3) | |
| Time to beginning of ART | −0.182 | 0.226 |
| Current use of protease inhibitors | 0.101 | |
| no | 9.8 (2.2) | |
| yes | 11.5 (2.7) | |
| Combination of ART with booster (ritonavir or cobicistat) | 0.827 | |
| no | 10.1 (2.4) | |
| yes | 9.9 (2.4) | |
| Virologic response to ART | 0.690 | |
| <20 copies/mL | 9.7 (2.2) | |
| 20–50 copies/mL | 10.1 (2.3) | |
| 50–200 copies/mL | 11.5 (3.5) | |
| >200 copies/mL | 10.7 (2.9) | |
| Immunologic response to ART | 0.035 * | |
| optimal | 9.3 (1.8) | |
| acceptable | 10.6 (2.6) | |
| not acceptable | 12.3 (2.9) | |
| ART discontinuation | 0.536 | |
| no | 10.2 (2.4) | |
| yes | 9.7 (2.3) | |
| IL-6 | 0.289 | 0.152 |
| PCR | −0.247 | 0.224 |
| VES | 0.194 | 0.354 |
| FBG | −0.053 | 0.789 |
Statistics: Pearson’s r or mean (SD). Abbreviations: HIV, Human immunodeficiency virus; ART, antiretroviral therapy; IL-6, interleukin-6; PCR, reactive C protein; VES, Erythrocyte sedimentation rate; FBG, fibrinogen. * only the comparison between “optimal” and “not acceptable” was statistically significant with a p = 0.040, by Dunnett correction using “not acceptable” as the reference category.